Abstract
Twelve years ago, the Mdm2 oncogene was shown to bind to and inhibit the tumor suppressor protein, p53. During the past 12 years, both genetic and biochemical studies have demonstrated that Mdm2 is a key negative regulator of the tumor suppressor p53. Mdm2 and p53 form an oscillating auto-regulatory feedback loop, which is tightly controlled to allow the appropriate response to environmental stresses in order to suppress tumor formation. When Mdm2 activity is inappropriately heightened, as it is in many human tumors, p53 activity is attenuated and tumor susceptibility arises. The p53 gene is mutated in 50% of all human tumors, but in those tumors that retain wild type p53, inhibiting Mdm2 activity could activate p53 tumor suppression and therefore provide a therapeutic strategy for the treatment of cancer.
Keywords: the tumor suppressor protein, p53, dna, transcriptional program, cell cycle arrest
Current Cancer Drug Targets
Title: MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Volume: 5 Issue: 1
Author(s): Gareth L. Bond, Wenwei Hu and Arnold J. Levine
Affiliation:
Keywords: the tumor suppressor protein, p53, dna, transcriptional program, cell cycle arrest
Abstract: Twelve years ago, the Mdm2 oncogene was shown to bind to and inhibit the tumor suppressor protein, p53. During the past 12 years, both genetic and biochemical studies have demonstrated that Mdm2 is a key negative regulator of the tumor suppressor p53. Mdm2 and p53 form an oscillating auto-regulatory feedback loop, which is tightly controlled to allow the appropriate response to environmental stresses in order to suppress tumor formation. When Mdm2 activity is inappropriately heightened, as it is in many human tumors, p53 activity is attenuated and tumor susceptibility arises. The p53 gene is mutated in 50% of all human tumors, but in those tumors that retain wild type p53, inhibiting Mdm2 activity could activate p53 tumor suppression and therefore provide a therapeutic strategy for the treatment of cancer.
Export Options
About this article
Cite this article as:
Bond L. Gareth, Hu Wenwei and Levine J. Arnold, MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting, Current Cancer Drug Targets 2005; 5 (1) . https://dx.doi.org/10.2174/1568009053332627
DOI https://dx.doi.org/10.2174/1568009053332627 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Application of Supercritical Fluid in Nanolithographic Processes
Recent Patents on Nanotechnology Patent Selections
Recent Patents on DNA & Gene Sequences Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties
Current Cancer Drug Targets Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies Editorial: Big Data and New Drug Discovery: Tackling “Big Data” for Virtual Screening of Large Compound Databases
Current Computer-Aided Drug Design Cancer Prevention with Green Tea Polyphenols for the General Population, and for Patients Following Cancer Treatment
Current Cancer Therapy Reviews Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Editorial (Thematic Issue: Applications of Peptides in Nanotechnology)
Current Topics in Medicinal Chemistry The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in Advanced Gastric Cancer: A Systematic Review and Pooled Analysis of the Chinese Literature
Current Cancer Therapy Reviews Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Synthetic and Application Perspectives of Azapodophyllotoxins: Alternative Scaffolds of Podophyllotoxin
Current Medicinal Chemistry Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Current Alzheimer Research Melanogenesis Inhibitors: Strategies for Searching for and Evaluation of Active Compounds
Current Medicinal Chemistry Vitamin D Receptor Signaling and Pancreatic Cancer Cell EMT
Current Pharmaceutical Design Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design